News

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Research being presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, is examining novel interventions that could address the growth in myopia.

Philip P. Storey, MD, shares the highlights of his ARVO presentation on a post hoc analysis of the pivotal TENAYA/LUCERNE trials.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.

With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.

Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.

Kelsey Roelofs, MD, shares some useful tips for identifying and diagnosing thyroid eye disease for attendees of the 18th Annual Controversies in Modern Eye Care symposium.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

Dr Richard Lindstrom speaks about the future of dry eye and shares pearls for young eye surgeons

The almost 474,000 participants in the study had been diagnosed with uveitis between January 1, 2015, and February 25, 2021 in South Korea.

The A-IOL aims to correct both near and distance eyesight, reduce reliance on glasses or contact lenses, have no glare or halos, and restore the eye’s ability to focus.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

Ahead of the meeting, several companies previewed product pipeline announcements and research data presentations

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

The meeting kicks off with symposia and an opening keynote speech from Ed Yong

Despite recognition of lenticular glutathione’s importance in lens formation for decades, why it declines with age remains a mystery.

According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.

The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Joseph Izatt was a skilled researcher and inventor who played a foundational role in the development of optical coherence tomography.

Several presentations will provide research updates on various topics related to retinal vein occlusion (RVO).

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Alcon was ordered to pay $34 million to Sight Sciences after a trial by jury.